Oramed Pharmaceuticals Inc (ORMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $161.33M
Last updated: Nov 17, 2026 at 11:05 AM ET
Oramed Pharmaceuticals Inc (ORMP) Earnings: Report Dates and Results
Oramed Pharmaceuticals (ORMP) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Oramed Pharmaceuticals reported EPS of -$0.16, below the $0.43 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ORMP has an expected report date of Mar 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 52.0% above the $0.25 reported for the quarter ended Dec 31, 2025.
Earnings History
Of the 35 quarters below that had an estimate, ORMP beat 21, missed 12 and matched 2. The widest gap in the table came in the quarter ended Jun 30, 2025, when EPS landed 875.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.16 | $0.43 | $0.43 - $0.43 | -137.21% | Miss | -114.2% | 1 | N/A | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.09 | $0.43 | $0.43 - $0.43 | -120.93% | Miss | -129.0% | 1 | N/A | Aug 10, 2026 | N/A |
| Mar 31, 2026 | $0.91 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 19, 2026 | N/A |
| Dec 31, 2025 | $0.25 | -$0.08 | N/A | +412.50% | Beat | N/A | 1 | 0 up, 0 down | Mar 26, 2026 | N/A |
| Sep 30, 2025 | $1.13 | -$0.04 | -$0.04 - -$0.04 | N/A | N/A | N/A | 1 | 0 up, 0 down | Nov 13, 2025 | N/A |
| Jun 30, 2025 | $0.31 | -$0.04 | N/A | +875.00% | Beat | +40.9% | N/A | 0 up, 0 down | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.19 | -$0.03 | N/A | -533.33% | Miss | -575.0% | N/A | 0 up, 0 down | May 15, 2025 | $2.00M |
| Dec 31, 2024 | -$0.26 | $0.02 | -$0.07 - $0.02 | N/A | N/A | -177.3% | 2 | 0 up, 0 down | Mar 27, 2025 | N/A |
| Sep 30, 2024 | -$0.48 | -$0.02 | -$0.02 - $0.03 | N/A | N/A | N/A | 2 | 0 up, 0 down | Nov 7, 2024 | N/A |
| Jun 30, 2024 | $0.22 | -$0.02 | -$0.02 - $0.04 | N/A | N/A | N/A | 2 | 0 up, 0 down | Aug 14, 2024 | N/A |
| Mar 31, 2024 | $0.04 | $0.02 | $0.02 - $0.02 | +100.00% | Beat | N/A | 1 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | $0.33 | -$0.12 | -$0.23 - -$0.01 | +375.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 6, 2024 | N/A |
| Sep 30, 2023 | -$0.08 | -$0.09 | -$0.09 - -$0.08 | +11.11% | Beat | N/A | 2 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.03 | -$0.09 | -$0.12 - -$0.09 | +66.67% | Beat | N/A | 3 | 0 up, 0 down | Aug 10, 2023 | $674000 |
| Mar 31, 2023 | -$0.08 | -$0.25 | -$0.29 - -$0.23 | +68.00% | Beat | N/A | 2 | 0 up, 0 down | May 11, 2023 | $666000 |
| Dec 31, 2022 | -$0.22 | -$0.23 | -$0.32 - -$0.16 | +4.35% | Beat | N/A | 5 | 0 up, 0 down | Mar 6, 2023 | $681000 |
| Sep 30, 2022 | -$0.18 | -$0.26 | -$0.30 - -$0.20 | +30.77% | Beat | N/A | 6 | 0 up, 0 down | Nov 10, 2022 | $682000 |
| Jun 30, 2022 | -$0.27 | -$0.24 | N/A | -12.50% | Miss | N/A | N/A | 0 up, 0 down | Aug 10, 2022 | $674000 |
| Mar 31, 2022 | -$0.27 | -$0.27 | N/A | 0.00% | In line | N/A | N/A | N/A | May 12, 2022 | $666000 |
| Dec 31, 2021 | -$0.22 | -$0.16 | N/A | -37.50% | Miss | N/A | N/A | N/A | Jan 11, 2022 | $674000 |
| Sep 30, 2021 | -$0.21 | -$0.18 | N/A | -16.67% | Miss | N/A | N/A | N/A | Nov 24, 2021 | $683000 |
| Jun 30, 2021 | -$0.17 | -$0.24 | N/A | +29.17% | Beat | N/A | N/A | N/A | Jul 14, 2021 | $681000 |
| Mar 31, 2021 | -$0.17 | -$0.17 | N/A | 0.00% | In line | N/A | N/A | N/A | Apr 13, 2021 | $665000 |
| Dec 31, 2020 | -$0.23 | -$0.19 | N/A | -21.05% | Miss | N/A | N/A | N/A | Jan 14, 2021 | $674000 |
| Sep 30, 2020 | -$0.12 | -$0.21 | N/A | +42.86% | Beat | N/A | N/A | N/A | Nov 24, 2020 | $681000 |
| Jun 30, 2020 | -$0.10 | -$0.20 | N/A | +50.00% | Beat | N/A | N/A | N/A | Jul 7, 2020 | $681000 |
| Mar 31, 2020 | -$0.21 | -$0.17 | N/A | -23.53% | Miss | N/A | N/A | N/A | Apr 6, 2020 | $674000 |
| Dec 31, 2019 | -$0.15 | -$0.23 | N/A | +34.78% | Beat | N/A | N/A | N/A | Jan 9, 2020 | $674000 |
| Sep 30, 2019 | -$0.13 | -$0.24 | N/A | +45.83% | Beat | N/A | N/A | N/A | Nov 27, 2019 | $681000 |
| Jun 30, 2019 | -$0.23 | -$0.24 | N/A | +4.17% | Beat | N/A | N/A | N/A | Jul 10, 2019 | $682000 |
| Mar 31, 2019 | -$0.21 | -$0.26 | N/A | +19.23% | Beat | N/A | N/A | N/A | Apr 10, 2019 | $666000 |
| Dec 31, 2018 | -$0.25 | -$0.19 | N/A | -31.58% | Miss | N/A | N/A | N/A | Jan 14, 2019 | $674000 |
| Sep 30, 2018 | -$0.18 | -$0.29 | N/A | +37.93% | Beat | N/A | N/A | N/A | Nov 28, 2018 | $617000 |
| Jun 30, 2018 | -$0.30 | -$0.27 | N/A | -11.11% | Miss | N/A | N/A | N/A | Jul 12, 2018 | $617000 |
| Mar 31, 2018 | -$0.20 | -$0.29 | N/A | +31.03% | Beat | N/A | N/A | N/A | Apr 8, 2018 | $604000 |
| Dec 31, 2017 | -$0.18 | -$0.21 | N/A | +14.29% | Beat | N/A | N/A | N/A | Jan 11, 2018 | $611000 |
| Sep 30, 2017 | -$0.20 | -$0.23 | N/A | +13.04% | Beat | N/A | N/A | N/A | Nov 29, 2017 | $618000 |
| Jun 30, 2017 | -$0.15 | -$0.27 | N/A | +44.44% | Beat | N/A | N/A | N/A | Jul 6, 2017 | $617000 |
| Mar 31, 2017 | -$0.24 | -$0.19 | N/A | -26.32% | Miss | N/A | N/A | N/A | Apr 5, 2017 | $611000 |
| Dec 31, 2016 | -$0.20 | -$0.12 | N/A | -66.67% | Miss | N/A | N/A | N/A | Jan 11, 2017 | $610000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.50, a profit after a loss of $0.48 per share the year before. It was -$0.86 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.50 | N/A |
| Dec 31, 2024 | -$0.48 | -439.4% |
| Dec 31, 2023 | $0.14 | N/A |
| Dec 31, 2022 | -$0.94 | N/A |
| Dec 31, 2021 | -$0.77 | N/A |
| Dec 31, 2020 | -$0.66 | N/A |
| Dec 31, 2019 | -$0.72 | N/A |
| Dec 31, 2018 | -$0.93 | N/A |
| Dec 31, 2017 | -$0.77 | N/A |
| Dec 31, 2016 | -$0.86 | N/A |
Frequently Asked Questions About ORMP
When is Oramed Pharmaceuticals's next earnings date?
Oramed Pharmaceuticals's next earnings report is expected for Mar 24, 2027.
Did ORMP beat earnings estimates last quarter?
No. Oramed Pharmaceuticals reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the $0.43 estimate by 137.21%.
What EPS do analysts expect from ORMP next quarter?
The consensus EPS estimate for Oramed Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.38 from 3 analysts, with estimates from $0.36 to $0.39.
How often does ORMP beat earnings estimates?
Oramed Pharmaceuticals beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +122.77%.
ORMP pages: Overview, Earnings, Forecast, Financials, Competitors